Patent application number | Description | Published |
20080199515 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders. | 08-21-2008 |
20090023680 | Fixed ratio drug combination treatments for solid tumors - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors. | 01-22-2009 |
20090074848 | COMBINATION FORMULATIONS OF CYTIDINE ANALOGS AND PLATINUM AGENTS - Compositions which comprise delivery vehicles having stably associated therewith a cytidine analog and a platinum agent are useful in achieving enhanced therapeutic effects when combinations of these drugs are administered. | 03-19-2009 |
20090098196 | LIPID CARRIER COMPOSITIONS WITH REDUCED POLY-DISPERSITY - The invention relates to a method for reducing the polydispersity of a population of gel-phase lipid-based delivery vehicles. | 04-16-2009 |
20090148506 | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR PREPARING THEREOF - Provided herein are liposomal compositions comprising a therapeutic agent having a protonatable amino group and a secondary or tertiary amine, and methods for encapsulating such therapeutic agents. In one aspect, the present invention relates to liposomal formulations comprising irinotecan in a triethanolamine solution, and optionally comprising copper gluconate, and methods for preparing the same. | 06-11-2009 |
20090304766 | LOCALIZED DELIVERY OF DRUG COMBINATIONS - Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non-antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed. | 12-10-2009 |
20100189771 | FIXED RATIO DRUG COMBINATION TREATMENTS FOR SOLID TUMORS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of irinotecan and floxuridine. Such methods are particularly useful in the treatment of cancer patients with advanced solid tumors. | 07-29-2010 |
20100303895 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS - Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders. | 12-02-2010 |
20110223241 | COMBINATION METHODS AND COMPOSITIONS - Compositions which comprise a liposomal water-soluble camptothecin and optionally a liposomal fluoropyrimidine in combination with a vascular epithelial growth factor (VEGF) inhibitor such as cetuximab or an epidermal growth factor receptor (EGFR) inhibitor such as bevacizumab are useful in achieving enhanced therapeutic effects for the treatment of cancer. | 09-15-2011 |
20120003294 | FIXED RATIO CAMPTOTHECENS/PLATINUM AGENTS - Compositions which comprise liposomes having controlled release of a platinum agent are useful in achieving enhanced therapeutic effects particularly when these drugs are administered in combination with other therapeutic agents. | 01-05-2012 |
20120009252 | LIPOSOMAL FORMULATIONS OF ANTHRACYCLINE AGENTS AND CYTIDINE ANALOGS - Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent. | 01-12-2012 |
20140255475 | METHOD OF LYOPHILIZING LIPOSOMES - Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution. | 09-11-2014 |